A Study on COVID-19 Prevention Force of Typical Cities in the Guangdong-Hong Kong-Macao Greater Bay Area Based on the Medical Perspective

doi:10.13523/j.cb.2108040

China Biotechnology

2021, Vol. 41

Issue (12): 125-140 DOI: 10.13523/j.cb.2108040

A Study on COVID-19 Prevention Force of Typical Cities in the Guangdong-Hong Kong-Macao Greater Bay Area Based on the Medical Perspective

FU Gui-e¹,LI Jin¹,GENG Pei-ran¹,SHEN Meng-qiu²,ZHANG Jin-qian-nan²,ZHAO Xi-chen^1,^**(

)

1 Macau University of Science and Technology, Macau S.A.R. 999078, China
2 China Science and Technology Exchange Center, Beijing 100045,China

Download:

HTML

PDF(2022KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

The COVID-19 epidemic that broke out at the end of 2019 has swept the world and seriously threatened human health. It has become a major global health and security challenge that requires the joint efforts of all countries in the world. Since different countries have different cultures, geographical locations, social systems, and economic development levels, their medical systems play different roles in epidemic prevention and control when facing the epidemic. Taking cities in the Guangdong-Hong Kong-Macao Greater Bay Area (Guangzhou, Shenzhen, Zhuhai, Hong Kong and Macau) under the epidemic situation as representatives, this paper aims to systematically summarize and quantitatively analyze the performance and effectiveness of various medical systems in public health emergencies, and to clarify the functions of medical institutions, medical staff, medical supplies, etc., as well as elucidate their advantages and shortcomings in the prevention and control of major infectious epidemics. The results show that in comparison to Hong Kong and Macao, the three cities in the mainland of China have a strong foundation of epidemic prevention medical system; Macao and the three cities in the mainland maintained a high degree of consistency in the early stage of the epidemic, and jointly promoted the mechanism of tackling key epidemic prevention problems, which performed well in the effectiveness of responding to the epidemic. However, due to the positioning restriction of the “international shipping center”and the impact of social tearing aftershocks, Hong Kong was difficult to quickly and comprehensively lock up, and the effectiveness of responding to the epidemic was slightly poor. In the future, Guangdong-Hong Kong-Macao Greater Bay Area should exchange and complement each other and share resources to jointly improve the public health emergency response capacity of the whole area.

Key words： COVID-19 Guangdong-Hong Kong-Macao Greater Bay Area Epidemic prevention force Medical system

Received: 16 August 2021 Published: 13 January 2022

ZTFLH:

R511R373.1

Corresponding Authors: Xi-chen ZHAO E-mail: xczhao@must.edu.mo

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Gui-e FU
	Jin LI
	Pei-ran GENG
	Meng-qiu SHEN
	Jin-qian-nan ZHANG
	Xi-chen ZHAO

Cite this article:

FU Gui-e,LI Jin,GENG Pei-ran,SHEN Meng-qiu,ZHANG Jin-qian-nan,ZHAO Xi-chen. A Study on COVID-19 Prevention Force of Typical Cities in the Guangdong-Hong Kong-Macao Greater Bay Area Based on the Medical Perspective. China Biotechnology, 2021, 41(12): 125-140.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.2108040 OR https://manu60.magtech.com.cn/biotech/Y2021/V41/I12/125

Table 1 Index system of epidemic prevention medical force of typical cities in the Guangdong-Hong Kong-Macao Greater Bay Area

Fig.1 Basic situation of medical resources in the typical cities

Table 2 Medical information systems scores in typical cities

Fig.2 Basic situation of medical service load in typical cities (a)The utilization rate of hospital beds in medical institutions (b)The average length of stay (c)The burden of doctors' diagnosis and treatment

Fig.3 Hospitalization and diagnosis of medical service load in typical cities (a)The hospitalization number (b)The diagnosis number

Fig.4 TCM medical services in typical cities (a)The number of TCM institutions (b)The number of TCM beds (c)The number of TCM personnel (d)The use of TCM beds

Fig.5 Basic situation of epidemic situation in typical cities (as of August 31, 2020),China

Table 3 Characteristics of infectious disease monitoring and prevention and control system in typical cities,China

Table 4 COVID-19 vaccine plan and score of typical cities (as of February 20, 2021),China^[25]

Table 5 Statistics of Delphi method weight opinions

Table 6 Weight of primary indicators

Table 7 Variability coefficient of each primary indicators

Table 8 The weight of epidemic prevention and medical strength of typical cities in the Guangdong-Hong Kong-Macao Greater Bay Area

一级指标	三级指标	总得分
一级指标	三级指标	广州市	深圳市	珠海市	香港	澳门
医疗资源8.6%	机构数(每10万人)	0.10	0.12	0.15	0.26	0.33
	医院(每10万人)	0.27	0.16	0.33	0.09	0.11
	三甲医院(每10万人)	0.50	0.05	0.24	0.21	0.35
	床位数(每千人)	0.50	0.29	0.38	0.42	0.18
	执业(助理)医师数(每千人)	1.88	1.48	1.88	0.98	1.33
	注册护士数(每千人)	0.91	0.59	0.78	1.41	0.66
	卫生技术人员数(每千人)	1.41	0.98	1.25	1.35	1.01
	医疗设备	0.36	0.45	0.27	0.45	0.27
	消杀用品	0.45	0.45	0.36	0.36	0.45
	防护用品	0.68	0.68	0.68	0.54	0.68
	防控药品	0.68	0.68	0.68	0.68	0.68
医疗信息系统20.55%	挂号系统	2.00	2.00	1.56	2.00	1.11
	电子病历	2.00	2.00	1.56	2.00	2.00
	电子健康档案	2.00	2.00	1.11	2.00	1.11
	新兴技术应用(物联网、大数据等)	9.20	9.20	7.16	9.20	5.11
	医疗物资储存系统	2.68	2.68	2.68	1.49	1.49
	医疗物资调配系统	2.68	2.68	1.49	1.49	2.68
医疗服务20.85%	总诊人次	1.09	0.72	0.13	0.25	0.02
	出入院人次	1.09	0.58	0.12	0.58	0.02
	平均住院日	0.93	1.08	0.94	1.07	1.09
	病床使用率(标准为85%)	1.08	1.06	1.08	1.08	1.01
	门诊	3.93	3.03	3.45	2.89	1.78
	住院	3.89	3.70	2.03	3.93	0.24
	中医院数(每10万人)	1.33	0.48	1.44	0.00	0.00
	中医门诊部、中医诊所	0.20	0.20	0.20	0.01	1.44
	中医诊疗人次(万次)	2.88	0.83	1.20	0.18	2.42
	中医医院执业(助理)医师数(千人)	2.85	1.93	2.88	2.29	2.31
	医疗系统现有能力分数小计	47.54	40.08	35.99	37.18	29.86
疫情25%	确诊率	7.92	7.99	7.79	1.98	7.66
	治愈率	8.20	8.28	8.11	7.52	8.33
	死亡率	7.97	6.82	6.21	4.00	8.33
疫情防控25%	传染病监控系统和防控措施	10.71	10.71	10.71	10.71	10.71
	核酸检测能力、费用	5.56	5.56	5.56	3.97	7.14
	新冠疫苗接种计划(及时性和公平性)	5.56	5.56	5.56	3.97	7.14
	医疗系统有效性分数小计	45.91	44.92	43.93	32.15	49.33
	合计总分	93.46	85.00	79.92	69.33	79.19

Table 9 Scores of epidemic prevention and medical strength of typical cities in the Guangdong-Hong Kong-Macao Greater Bay Area

Fig.6 Comparison of epidemic prevention medical forces in typical cities in the Guangdong-Hong Kong-Macao Greater Bay Area,China


[1]	世卫组织. 世卫组织应对COVID-19疫情时间线[EB/OL].[2020-03-11]. https://www.who.int/zh/news/item/29-06-2020-covidtimeline.

[1]	World Health Organization. Who deal with COVID - 19 outbreak time line [EB/OL] [2020-03-11]. https://www.who.int/zh/news/item/29-06-2020-covidtimeline.

[2]	习近平. 在中央政治局常委会会议研究应对新型冠状病毒肺炎疫情工作时的讲话. 求是, 2020(4): 1.

[2]	Xi J P. At the meeting of the Standing Committee of the Standing Committee of the Politburo, to study the speech of New Coronavirus pneumonia. QIUSHI, 2020(4): 1.

[3]	武汉大学国家发展战略研究院新冠病毒疫情防控研究课题组. 抗击新冠病毒疫情的中国经验. 学习与实践, 2020(4): 22-34.

[3]	COVID-19 Research and Prevention Research Group, National Development Strategy Institute, Wuhan University. Research on China’s experience in fighting the COVID-19 epidemic. Study and Practice, 2020(4): 22-34.

[4]	陈培彬, 王丹凤, 钟旻桦, 等. 农村突发公共卫生事件应急管理能力评价. 统计与决策, 2021, 37(15): 156-160.

[4]	Chen P B, Wang D F, Zhong M H, et al. Evaluation on capability of rural public health emergency management. Statistics & Decision, 2021, 37(15): 156-160.

[5]	朱伟红, 郭伟强. 广东省高水平医院建设策略对医院医疗服务能力的提升. 现代医院, 2021, 21(7): 1043-1045, 1048.

[5]	Zhu W H, Guo W Q. Improvement of medical service capacity of Y hospital by the strategy of building a high-level hospital. Modern Hospitals, 2021, 21(7): 1043-1045, 1048.

[6]	广东省卫生健康委政务服务中心. 2019年广东省医疗卫生资源和医疗服务情况简报. [2020-04-18]. http://wsjkw.gd.gov.cn/zwgk_tjxx/content/post_3000814.html.

[6]	Government affairs service center of Guangdong Provincial Health Commission. Briefing on medical and health resources and medical services in Guangdong Province in 2019. [2020-04-18]. http://wsjkw.gd.gov.cn/zwgk_tjxx/content/post_3000814.html.

[7]	赵丹丹. 上海市医疗资源及其纵向整合现状分析. 中国卫生资源, 2008, 11(6): 259-262.

[7]	Zhao D D. The reality and preliminary analysis on medical resources and their vertical integration in Shanghai. Chinese Health Resources, 2008, 11(6): 259-262.

[8]	胡晓伟, 宋浪, 杨滨毓, 等. 重大突发公共卫生事件下城市应急医疗物资优化调度研究. 中国公路学报, 2020, 33(11): 55-64.

[8]	Hu X W, Song L, Yang B Y, et al. Optimal matching of urban emergency medical supplies under major public health events. China Journal of Highway and Transport, 2020, 33(11): 55-64.

[10]	王青兰, 王喆, 曲强. 新型国家公共卫生信息系统建设:提高系统韧性的思考. 改革, 2020(4): 17-27.

[10]	Wang Q L, Wang Z, Qu Q. The construction of new national public health information system: reflections on improving the system resilience. Reform, 2020(4): 17-27.

[11]	沈兵, 尤健, 李晶慧, 等. 大型城市应急医疗物资保障体系建设的问题与对策. 中国医院管理, 2020, 40(4): 1-4.

[11]	Shen B, You J, Li J H, et al. Problems of establishment of emergency medical supplies system in mega-cities and the countermeasures. Chinese Hospital Management, 2020, 40(4): 1-4.

[12]	汤文巍, 程晓明. 医疗服务产业投资分析. 中国卫生资源, 2005, 8(3): 102-104.

[12]	Tang W W, Cheng X M. Analysis on medical service industry investment. Chinese Health Resources, 2005, 8(3): 102-104.

[13]	谢洋, 王佳佳, 赵虎雷, 等. 基于德尔菲法的新型冠状病毒肺炎中医辨证规范专家问卷分析. 中医学报, 2020, 35(4): 699-703.

[13]	Xie Y, Wang J J, Zhao H L, et al. Expert questionnaire analysis of TCM syndrome differentiation standard for COVID-19 based on Delphi method. Acta Chinese Medicine, 2020, 35(4): 699-703.

[14]	郭金玉, 张忠彬, 孙庆云. 层次分析法的研究与应用. 中国安全科学学报, 2008, 18(5): 148-153.

[14]	Guo J Y, Zhang Z B, Sun Q Y. Study and applications of analytic hierarchy process. China Safety Science Journal (CSSJ), 2008, 18(5): 148-153.

[15]	申一帆, 胡善联, 黄炯烈, 等. 1980年~2001年广州市医疗资源配置和利用效率分析. 中华医院管理杂志, 2004(6): 361-365.

[15]	Shen Y F, Hu S L, Huang J L, et al. Analysis of medical resources allocation and service efficiency in Guangzhou from 1980 to 2001. Chinese Journal of Hospital Administration, 2004(6): 361-365.

[16]	Shao F, Fan K L, Robertson C, et al. Comparison of two emergency medical services in Beijing and Hong Kong, China. Chinese Medical Journal, 2019, 132(11): 1372-1374. doi: 10.1097/CM9.0000000000000252 pmid: 31157676

[17]	章含青, 王萱萱, 陈家应, 等. 深圳市卫生资源配置现状与优化策略研究. 南京医科大学学报(社会科学版), 2021, 21(3): 213-217.

[17]	Zhang H Q, Wang X X, Chen J Y, et al. Research on the status quo and optimization strategies of health resources in Shenzhen. Journal of Nanjing Medical University (Social Sciences), 2021, 21(3): 213-217.

[18]	王春新. 2019 年香港经济形势及2020年展望:兼论修例风波及新冠肺炎疫情对香港经济的影响. 港澳研究, 2020(2): 62-72, 95.

[18]	Wang C X. Hong kong's economic situation in 2019 and the outlook in 2020: the impact of the extradition law protest and COVID-19 on Hong kong's economy. Hong Kong and Macao Journal, 2020(2): 62-72, 95.

[19]	Lai Y F, Chen S Q, Li M, et al. Policy interventions, development trends, and service innovations of Internet hospitals in China: documentary analysis and qualitative interview study. Journal of Medical Internet Research, 2021, 23(7): e22330. doi: 10.2196/22330

[20]	Di Lauro F, Kiss I Z, Rus D, et al. Covid-19 and flattening the curve: a feedback control perspective. IEEE Control Systems Letters, 2021, 5(4): 1435-1440. doi: 10.1109/LCSYS.2020.3039322

[21]	Feng Z T, Yang J, Xu M Z, et al. Dietary supplements and herbal medicine for COVID-19: a systematic review of randomized control trials. Clinical Nutrition ESPEN, 2021, 44: 50-60. doi: 10.1016/j.clnesp.2021.05.018

[22]	Liang S B, Fang M, Liang C H, et al. Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: a rapid systematic review and meta-analysis of randomized controlled trials. Complementary Therapies in Medicine, 2021, 60: 102744. doi: 10.1016/j.ctim.2021.102744

[23]	王林群, 胡刚明, 巴元明, 等. “肺炎1号”联合西医常规治疗新型冠状病毒肺炎的回顾性研究. 中国中医急症, 2021, 30(1): 10-12.

[23]	Wang L Q, Hu G M, Ba Y M, et al. A retrospective study on the treatment of coronavirus disease 2019 with “pneumonia No.1” combined with conventional western medicine. Journal of Emergency in Traditional Chinese Medicine, 2021, 30(1): 10-12.

[24]	Wang Q, Yang L Q, Jin H, et al. Vaccination against COVID-19: a systematic review and meta-analysis of acceptability and its predictors. Preventive Medicine, 2021, 150: 106694. doi: 10.1016/j.ypmed.2021.106694

[25]	广东省卫生健康委员会. 2020年广东省医疗卫生资源和医疗服务情况简报. [2021-07-02]. http://wsjkw.gd.gov.cn/zwgk_tjxx/content/post_3274161.html.

[25]	The Health Committee of Guangdong Province. In 2020, Guangdong province, medical and health resources, and medical service debriefings. [2021-07-02]. http://wsjkw.gd.gov.cn/zwgk_tjxx/content/post_3274161.html.

[26]	梅小亚, 赵林畅. 大数据在重大流行病疫情防控中的应用及展望. 河海大学学报(哲学社会科学版), 2020, 22(2): 39-47, 106.

[26]	Mei X Y, Zhao L C. Application and prospect of big-data in prevention and control of major epidemics. Journal of Hohai University (Philosophy and Social Sciences), 2020, 22(2): 39-47, 106.

[27]	广州日报. “十三五”期间广州市公共卫生服务能力显著增强.[2021-5-30]. http://www.gz.gov.cn/zwfw/zxfw/ylfw/content/post_6871750.html.

[27]	Guangzhou Daily. During the period of “much starker choices-and graver consequences-in” Guangzhou will markedly enhance its capability of public health services. [2021-5-30]. http://www.gz.gov.cn/zwfw/zxfw/ylfw/content/post_6871750.html.

[28]	佚名. 广东:智慧医疗让科技为服务添翼. 电子技术与软件工程, 2014(17): 6.

[28]	Anonymous. Guangdong: Smart Medicine lets technology add wings to services. Electronic Technology & Software Engineering, 2014(17): 6.

[29]	陈志威, 曹洪欣, 蔡秋杰, 等. 互联网+中医药诊疗防治新冠肺炎的实践与思考. 中国卫生信息管理杂志, 2021, 18(1): 123-126.

[29]	Chen Z W, Cao H X, Cai Q J, et al. Practice and thinking of “Internet+TCM healthcare” in COVID-19’s prevention and treatment. Chinese Journal of Health Informatics and Management, 2021, 18(1): 123-126.

[30]	袁永, 康捷, 唐慧. 广东应对新冠肺炎疫情的科技创新政策研究. 科技创新发展战略研究, 2021, 5(2): 20-23.

[30]	Yuan Y, Kang J, Tang H. Research on guangdong’s scientific and technological innovation policies in response to the COVID-19 epidemic. Strategy for Innovation and Development of Science and Technology, 2021, 5(2): 20-23.

[31]	王刚, 张晋周, 柏磊. 深圳战疫的成绩与启示. 特区实践与理论, 2021(3): 47-52.

[31]	Wang G, Zhang J Z, Bai L. Achievements and enlightenment of war epidemic in Shenzhen. Practice and Theory of SEZS, 2021(3): 47-52.

[32]	李岱素, 潘慧. “深圳智造”用实力彰显中国制造风采. 广东科技, 2017, 26(8): 41.

[32]	Li D S, Pan H. “Shenzhen smart manufacturing” demonstrates the style of made in China with strength. Guangdong Science & Technology, 2017, 26(8): 41.

[33]	钟莹, 林秋梅. 深圳港2020年货物吞吐量及集装箱吞吐量逆势上涨. 珠江水运, 2021(2): 34.

[33]	Zhong Y, Lin Q M. Counter trend rises in cargo throughput and container throughput of Shenzhen port in 2020. Pearl River Water Transportation, 2021(2): 34.

[34]	广东省社会科学界联合会中国(深圳)综合开发研究院联合课题组. 从新冠疫情防控看我国超大城市治理现代化的“三个能力”建设: 深圳的视角. 新经济, 2020(11): 23-30, 2.

[34]	Joint Research Group of Guangdong (Shenzhen) Comprehensive Development Research institute of the Federation of Social Sciences in Shenzhen. From the view of COVID-19’s prevention and control, we can see the construction of the “Three Abilities” of China’s modernization of Super City: from the perspective of Shenzhen. New Economy, 2020(11): 23-30, 2.

[35]	深圳新闻网. 深圳推进全民健康信息化 “12361”实现互联互通医疗资源共享. [2020-12-21]. http://www.sznews.com/news/content/2019-09/02/content_22435792.htm.

[35]	Shenzhen News Network. Shenzhen promotes National Health Informatization “12361” to realize interconnection and sharing in medical resources. [2020-12-21]. http://www.sznews.com/news/content/2019-09/02/content_22435792.htm.

[36]	彭兰. 新冠疫情中政务微信的信息发布:以“珠海发布”为例. 新闻前哨, 2020(4): 17-19.

[36]	Peng L. New outbreaks in e-government WeChat information release-“Zhuhai released”, for example. Press Outpost, 2020(4): 17-19.

[37]	胡皓琼. 坚守香港国际航运中心地位:专访香港运输及房屋局局长陈帆. 中国航务周刊, 2021(30): 28-30.

[37]	Hu H Q. Hong Kong’s Status as an international shipping center: An interview with secretary for Transport and Housing Chen Fan. China Shipping Gazette, 2021(30): 28-30.

[38]	香港政. 香港医疗体制简介.[2020-12-12]. https://www.gov.hk/sc/residents/health/hosp/overview.htm.

[38]	Hong Kong Politics. Introduction of Hong Kong’s health care system. [2020-12-12]. https://www.gov.hk/sc/residents/health/hosp/overview.htm.

[39]	Daniels R S, Tse H, Ermetal B, et al. Molecular characterization of influenza C viruses from outbreaks in Hong Kong SAR, China. Journal of Virology, 2020, 94(21). DOI: 10.1128/jvi.01051-20. doi: 10.1128/jvi.01051-20

[40]	Wong S Y S, Tan D H Y, Zhang Y, et al. A tale of 3 Asian cities: how is primary care responding to COVID-19 in Hong Kong, Singapore, and Beijing? The Annals of Family Medicine, 2021, 19(1): 48-54. doi: 10.1370/afm.2635

[41]	Keck F. Asian tigers and the Chinese dragon: Competition and collaboration between sentinels of pandemics from SARS to COVID-19. Centaurus, 2020, 62(2): 311-320. doi: 10.1111/cnt.v62.2

[42]	Ahmed S F, Quadeer A A, McKay M R. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses, 2020, 12(3): 254. doi: 10.3390/v12030254

[43]	Hung I F N, Lung K C, Tso E Y K, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial. Lancet, 2020, 395(10238): 1695-1704. doi: 10.1016/S0140-6736(20)31042-4

[44]	郑亮, 陈以乐. 澳门城市在突发公共卫生事件期间的状况及对策分析. 城市住宅, 2021, 28(1): 98-103.

[44]	Zheng L, Chen Y L. Analyze Macao city during public health emergencies and countermeasures. City & House, 2021, 28(1): 98-103.

[45]	陈乐怡, 毛爱妹. 2020年澳门地区新冠肺炎边境管制措施之成效及省思. 疫情报道, 2020, 36(22): 358-365.

[45]	Chen L Y, Mao A M. The effectiveness and review of COVID-19 border control measures in Macao in 2020. Chin J Epidemiol, 2020, 36(22): 358-365.

[46]	白彦锋, 李泳禧. 澳门新冠肺炎疫情应急机制与应急财政启示. 地方财政研究, 2020(4): 26-35.

[46]	Bai Y F, Li Y X. COVID-19 emergency mechanism and financial inspiration in Macao. Sub National Fiscal Research, 2020(4): 26-35.

[1]	YUN Tao,GONG Yue,GU Peng,XU Bing-bing,LI Jin,ZHAO Xi-chen. Present Situation and Prospect of International S&T Cooperation between China and Countries Participating in the “Belt and Road” Initiative to Combat COVID-19[J]. China Biotechnology, 2021, 41(7): 110-121.

[2]	TAN Qing-li,LIN Dai-heng,LIU Jia-yuan,LIN Xing-chun. Study on the Benefits of Biomedical Industry in the Guangdong-Hong Kong-Macao Greater Bay Area Based on Grey Comprehensive Correlation Analysis[J]. China Biotechnology, 2021, 41(6): 89-97.

[3]	XU Ye-chun,LIU Hong,LI Jian-feng,SHEN Jing-shan,JIANG Hua-liang. Recent Progress in Drug Development against COVID-19[J]. China Biotechnology, 2021, 41(6): 111-118.

[4]	WU Rui-jun,LI Zhi-fei,ZHANG Xin,PU Run,AO Yi,SUN Yan-rong. Development and Prospect of Antibody Drugs for SARS-CoV-2[J]. China Biotechnology, 2020, 40(5): 1-6.

[5]	XIE Hua-ling,LV Lu-cheng,YANG Yan-ping. Patent Analysis of Global Coronavirus Vaccine[J]. China Biotechnology, 2020, 40(1-2): 57-64.

[6]	ZHU Xiao-li,HUANG Cui,MA Li-li,ZHANG Chao,GONG Yue,ZHAO Wan-yu,ZHAO Xiu-fang,GUO Wen-jiao,PENG Hao,ZHANG Ji,LIANG Hui-gang. Research Advances of Novel Coronavirus Disease (COVID-19)[J]. China Biotechnology, 2020, 40(1-2): 38-50.

[7]	LIN Fu-yu,LIU Jin-yi,CHENG Yong-qing. Progress of Interferon α1b Research and Clinical Use Against SARS-CoV-2[J]. China Biotechnology, 2020, 40(12): 1-7.

[8]	LIAO Xiao-yan,CHEN Li-li. The Progress in the Development of COVID-19 Vaccine[J]. China Biotechnology, 2020, 40(12): 8-17.

[9]	CHEN Li-jun,QU Jing-jing,XIANG Charlie. Therapeutic Potentials, Clinical Studies, and Application Prospects of Mesenchymal Stem Cells in 2019 Novel Coronavirus (COVID-19)[J]. China Biotechnology, 2020, 40(11): 43-55.

Viewed

Full text

Abstract

Cited

Shared

Discussed